Polaryx Therapeutics, Inc. Common Stock (PLYX) investor relations documents from the company's IR site: 3 presentations, 1 press release. Read in-app with summaries. First-party data.
Presentation: Polaryx Therapeutics (Nasdaq: PLYX) is a clinical-stage biotech developing PLX-200, an oral small molecule for Lysosomal Storage Disorders (LSDs).
| Published | Type | Document |
|---|---|---|
| 2026-08-13 | Quarterly report | Q2 2026 Quarterly Report |
| 2026-02-03 | Press release | Polaryx to Present Late-Breaker Data Related to SOTERIA at the 22nd Annual WORLDSymposium™ |
| 2026-02-02 | Prospectus | PDF - Prospectus [Rule 424(b)(4)] |
| Presentation | Presentation | |
| Presentation | Presentation | |
| Presentation | https://storage.googleapis.com/vendorgroup-assets/site/f2ca1d02-b66c-41df-9ec1-d2bfc64b0a36/2026/05/08/69fddbf0f08a11a5891fd3e5/Polaryx Therapeutics Corporate Presentation_May 2026.pdf |
PLYX overview · PLYX earnings · PLYX financials · PLYX KPIs · PLYX ownership · PLYX peers · PLYX filings
Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.